279 related articles for article (PubMed ID: 16340936)
41. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
[TBL] [Abstract][Full Text] [Related]
42. Anemia management and chronic renal failure progression.
Rossert J; Froissart M; Jacquot C
Kidney Int Suppl; 2005 Dec; (99):S76-81. PubMed ID: 16336582
[TBL] [Abstract][Full Text] [Related]
43. [Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease].
Wanic-Kossowska M
Pol Merkur Lekarski; 2010 Jan; 28(163):13-7. PubMed ID: 20369716
[TBL] [Abstract][Full Text] [Related]
44. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
[TBL] [Abstract][Full Text] [Related]
45. A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin.
Kamar N; Guitard J; Ribes D; Esposito L; Rostaing L
Exp Clin Transplant; 2008 Dec; 6(4):271-5. PubMed ID: 19338488
[TBL] [Abstract][Full Text] [Related]
46. [Erythropoiesis stimulating agents in clinical practice].
Niemczyk L; Dębowska M
Wiad Lek; 2014; 67(3):413-5. PubMed ID: 25782201
[TBL] [Abstract][Full Text] [Related]
47. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
Hymes J; Bickimer T; Jackson JH; Bookhart BK; Mody SH; Tak Piech C
Curr Med Res Opin; 2007 Aug; 23(8):1931-7. PubMed ID: 17624232
[TBL] [Abstract][Full Text] [Related]
48. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
[No Abstract] [Full Text] [Related]
49. Darbepoetin alfa: a new therapeutic agent for renal anemia.
Macdougall IC
Kidney Int Suppl; 2002 May; (80):55-61. PubMed ID: 11982814
[TBL] [Abstract][Full Text] [Related]
50. Effects of Epoetin alfa on hemostasis in chronic renal failure.
Tang WW; Stead RA; Goodkin DA
Am J Nephrol; 1998; 18(4):263-73. PubMed ID: 9653828
[TBL] [Abstract][Full Text] [Related]
51. Erythropoiesis-stimulating agents in kidney and cardiac disease.
Fluck R
Br J Hosp Med (Lond); 2006 Oct; 67(10):533-7. PubMed ID: 17069130
[No Abstract] [Full Text] [Related]
52. Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction.
Howlett JG
Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):199-208. PubMed ID: 18248274
[TBL] [Abstract][Full Text] [Related]
53. Emerging drugs for treatment of anemia of chronic kidney disease.
Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
[TBL] [Abstract][Full Text] [Related]
54. Long-acting erythropoietin stimulating agents for persistent anemia after kidney transplant: risk factors and outcome.
Al-Otaibi T; Gheith O; Halim MA; Abu Attia H; Mansour H; Said T; Nair P; Balaha M; Nampoory MR
Exp Clin Transplant; 2014 Jun; 12(3):220-6. PubMed ID: 24907722
[TBL] [Abstract][Full Text] [Related]
55. Darbepoetin alfa treatment for post-renal transplantation anemia during pregnancy.
Goshorn J; Youell TD
Am J Kidney Dis; 2005 Nov; 46(5):e81-6. PubMed ID: 16253714
[TBL] [Abstract][Full Text] [Related]
56. Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa.
Scott SD
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):129S-132S. PubMed ID: 12222582
[No Abstract] [Full Text] [Related]
57. The use of darbepoetin to stimulate erythropoiesis in anemia of chronic kidney disease in cats: 25 cases.
Chalhoub S; Langston CE; Farrelly J
J Vet Intern Med; 2012; 26(2):363-9. PubMed ID: 22296687
[TBL] [Abstract][Full Text] [Related]
58. Treatment of anemia with epoetin in kidney transplant recipients.
Bren A; Arnol M; Kandus A; Varl J; Oblak M; Lindič J; Pajek J; Knap B; Kovač D; Mlinšek G; Buturović-Ponikvar J
Ther Apher Dial; 2011 Jun; 15(3):257-60. PubMed ID: 21624072
[TBL] [Abstract][Full Text] [Related]
59. Erythropoietin in kidney disease and type 2 diabetes.
Thum T; Kalantar-Zadeh K; Anker SD
N Engl J Med; 2011 Jan; 364(4):384-5; author reply 385-6. PubMed ID: 21268744
[No Abstract] [Full Text] [Related]
60. [Pharmacological and clinical profiles of long-lasting erythropoiesis-stimulating agent (darbepoetin alfa; NESP].
Nagano N
Nihon Yakurigaku Zasshi; 2008 Apr; 131(4):291-9. PubMed ID: 18408341
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
